

FOI 2592

12th September 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Response:

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	13
1.2 Alpelisib (Piqray)	0
1.3 Fulvestrant (fulvestrant or Faslodex)	Info not held by pharmacy
1.4 Palbociclib (Ibrance)	31
1.5 Ribociclib (Kisqali)	15
1.6 Capivasertib (Truqap)	0

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Response:

Number patients treated
11

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Response:

Treatment intent	Number patients treated
3.1 Curative	11
3.2 Palliative	2
3.3 Not known / stated	0

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Response:

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	1
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	6
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	4

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of April 2024 and end of June 2024?

Response:

Type of breast cancer	Number patients treated
5.1 all types of breast cancer	1
5.2 adjuvant treatment for early breast cancer	0

Q6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
6.1 Abiraterone (Zytiga or generic abiraterone)	6
6.2 Apalutamide (Erleada)	0
6.3 Cabazitaxel (Jevtana or generic cabazitaxel)	2
6.4 Darolutamide (Nubeqa)	6
6.5 Enzalutamide (Xtandi)	61

Q7. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
Docetaxel for prostate cancer	8
Olaparib (Lynparza) for prostate cancer	0

Q8. How many patients were treated with the following medicine combinations in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
8.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	Info not held by pharmacy
8.2 Apalutamide (Erleada) + Androgen Deprivation Therapy	0
8.3 Darolutamide (Nubeqa) + Docetaxel + ADT	Info not held by pharmacy
8.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy	Info not held by pharmacy
8.5 Olaparib (Lynparza) + Abiraterone	0

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

OVARIAN and ENDOMETRIAL CANCERS

Q9. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
9.1 Dostarlimab (Jemperli)	0
9.2 Niraparib (Zejula)	0
9.3 Rucaparib (Rubraca)	0
9.4 Olaparib (Lynparza)	0

Q10. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
10.1 Olaparib in total	0
10.2 Olaparib monotherapy	0
10.3 Olaparib + bevacizumab in combination	0
10.4 Bevacizumab total	0
10.5 Bevacizumab monotherapy	0
10.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	0

Email: Foi.Team@Southerntrust.hscni.net